凝血酶Arg221aTrp突变破坏Na+结合并优先损害抗凝功能
该研究通过重组DNA、酶学、光谱及分子建模等多技术手段,定量分析了重组α-凝血酶Arg221aTrp突变体(αT-PD2)对促凝和抗凝通路的影响。结果发现该突变消除生理性Na+结合,促凝功能(纤维蛋白生成、血小板活化)和抗凝功能(ATIII抑制、肝素结合、蛋白C活化)均受损,但抗凝通路受损更显著(蛋白C活化降低41倍)。结论提示该突变携带者的促血栓表型源于对抗凝通路的抑制占主导,使体内凝血平衡向血栓方向偏移。
要点
- Arg221aTrp突变消除α-凝血酶生理性Na+结合并减少完全活性构象比例。
- 突变体促凝功能受损:纤维蛋白生成降低7倍,血小板活化降低10倍。
- 抗凝功能受损更显著:ATIII抑制降低3倍,肝素结合降低10倍,蛋白C活化降低41倍。
核心结论
- Arg221aTrp突变携带者的促血栓表型可能源于该突变同时抑制促凝和抗凝通路,但对抗凝通路的抑制占主导,使体内凝血-抗凝平衡向血栓方向偏移。
研究设计与样本
- 采用重组DNA技术、凝血/纤溶及酶学测定、显微镜、蛋白质组学、光谱、质谱和分子建模等多技术整合方法,对重组α-凝血酶Arg221aTrp突变体(αT-PD2)进行定量研究。
主要发现
- Arg221aTrp突变消除生理性Na+结合并降低完全活性α-凝血酶构象的比例。
- αT-PD2促凝功能受损:生成纤维蛋白的效率降低7倍,活化血小板的效率降低10倍。
- αT-PD2抗凝功能受损更显著:被ATIII抑制的效率降低3倍,与肝素结合减弱10倍,活化蛋白C的效率降低41倍。
临床怎么用
- 对于携带凝血酶原Arg596(对应α-凝血酶Arg221a)突变的患者,应认识到其血栓风险可能主要源于抗凝通路受损,而非单纯促凝增强。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Natural mutations in the prothrombin gene, involving the substitution of Arg596 with polar/apolar amino acids, represent an important risk factor for thrombosis. Notably, Arg596 in prothrombin corresponds to position 221a in the Na+-binding loop of mature α-thrombin (αT). Patients carrying these mutations (Arg221a→Gln/Leu/Trp) share a common clinical phenotype, characterized by a moderately reduced procoagulant function in coagulation tests and resistance of αT variants to inactivation by antithrombin III (ATIII). However, the biochemical mechanisms linking these mutations to the increased thrombotic risk remain elusive. OBJECTIVES: To provide quantitative data on the effect that the recombinant Arg221aTrp αT mutant (αT-PD2) has on the activation of procoagulant and anticoagulant pathways and elucidate the structural basis of the observed functional changes. METHODS: A multipronged approach was used, integrating recombinant DNA techniques, clotting/fibrinolytic and enzymatic assays, microscopy, proteomics, spectroscopic, mass spectrometry, and molecular modeling techniques. RESULTS: Arg221aTrp mutation abrogates physiological Na+ binding and reduces the proportion of the fully active αT conformation. αT-PD2 affects procoagulant pathways by less efficiently generating fibrin (7-fold) and activating platelets (10-fold). The mutation potently affects anticoagulant pathways, as αT-PD2 is less efficiently inhibited by ATIII (3-fold), binds heparin less tightly (10-fold), and much less efficiently (41-fold) activates protein C. CONCLUSION: Our data indicate that the procoagulant phenotype, observed in Arg221aTrp mutation carriers, may result from opposing inhibitory effects on both procoagulant and anticoagulant pathways, with the impact on anticoagulant pathways being predominant and shifting the natural anticoagulant↔procoagulant equilibrium in vivo toward thrombosis.
引用
- Acquasaliente L, Pierangelini A, Uliana F, et al. The natural mutation Arg221aTrp in human α-thrombin abrogates physiological Na+ binding and preferentially hinders the protease anticoagulant functions. J Thromb Haemost. 2026. PMID: 42372952. doi:10.1016/j.jtha.2026.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。